NOACs In Long-term VTE Treatment: A State Of The Art Review

Slides:

Advertisements

Similar presentations

Addressing the Challenges in Primary and Secondary Stroke Prevention

Advertisements

Oral Anticoagulants and Reversal Agents

NOACs for Cancer-Associated Thrombosis:

Anticoagulants in Interventional Cardiology:

Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.

Making Decisions With Your Osteoarthritis Patients

Long-Term Treatment of VTE: Case Studies

US Guidelines US Guidelines Low-risk Patients.

When Is Adding Aspirin to NOACs Worth the Risk?

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

Thrombosis, Cancer, and NOACs

Expert Perspectives on Clinically Challenging Cases in Narcolepsy

The ABCs of AF.

Access to NOAC Therapy:

NOACs in Clinical Practice: Are They All the Same?

Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

Emergency Management of NOAC Bleeding

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

Anticoagulation Highlights From the American Heart Association Meeting 2017.

Up to Date on Which NOAC for Which Patient

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

New Perspectives in CAD and PAD: Weighing the Latest Evidence

Oral Anticoagulants in AFa,b A Brief History.

Surveying the Safety of NOACs in the Real World

Selecting NOACs for High-Risk Patients

A Case Challenge: Anticoagulant Choices for Acute PE

The Essentials for Secondary Stroke Prevention

Assessing the Risk for Stroke in Patients With Atrial Fibrillation

Are We Closer to Personalized Medicine in MS?

New Oral Anticoagulants and VTE Management

VTE Treatment Conventional Approach

Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.

AF and PCI in Practice.

Access to NOAC Therapy:

Program Goals. Treatment-Naive Patients With PAH What Do We Know and What Choices Do We Have?

TAVR and the Risk of Thrombosis

What Anticoagulant Registries Are Revealing

Learning Objectives Classification of VTE Goals of VTE Treatment.

A Better Solution For Cancer Patients With VTE?

Reversal Strategies for VKA: Truths and Misconceptions

Oral Anticoagulation in AF

Forest plot of the HRs for DOACs vs warfarin for (A) new or recurrent VTE and (B) major bleeding based on the published subanalyses of the patients with.

Real-World Evidence in VTE

Extending Treatment for Thrombosis: What’s the Right Choice?

Practical Considerations to Extend Treatment for VTE

Extraordinary Cases of VTE Prevention in Patients With Cancer

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

Anticoagulation and Thrombosis Management

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Identifying High-Risk AF Patients

Factor Xa Inhibitors in PAD

A Time for Change for Managing Patients With VTE Who Have Cancer

Cancer-Associated Thrombosis

Managing Pulmonary Embolism Posthospital Discharge

NOAC Studies in VTE AF Studies Superior Outcomes.

Extraordinary Cases in VTE

Program Goals Background: Anticoagulation in Patients With VTE.

Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE.

Clinical Challenges and Updates in Managing Seizure Clusters

The ABCs of AF.

Disease Burden of VTE Phases of VTE Treatment.

At the Crossroads of Coagulation

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

Perspectives on Revised European Guidelines on Management of Bleeding and Coagulopathy Following Major Trauma.

Extraordinary Cases in Stroke Prevention

What's New in NOACs in AF?.

Treating Pulmonary Embolism Today

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Presentation transcript:

NOACs In Long-term VTE Treatment: A State Of The Art Review

Introduction

Most Common Causes of VTE

Burden of VTE

Burden of VTE in the European Union

Recurrent VTE After Discontinuation of Anticoagulation

Antithrombotic Therapy for VTE: CHEST Guideline and Expert Panel Report

VTE Treatment Phases

Risk Factors for Recurrence After a First VTE Event

Strategies for Preventing Recurrence of VTE

Strategies for Preventing Recurrence of VTE (cont)

Strategies for Preventing Recurrence of VTE (cont)

Risk Scoring Algorithms for VTE Recurrence[a]

Role of VTE Risk Stratification Tools

Conventional Treatment of VTE: Advantages and Disadvantages

Antithrombotic Therapy for VTE: CHEST Guideline and Expert Panel Report

Key Clinical Trials of NOACs in the Secondary Prevention of VTE

Advantages of NOACs vs Conventional Therapy in the Secondary Prevention of VTE

Potential Concerns Regarding the Use of NOACs in the Management of VTE

Variation in NOAC Administration Based on Methodologies of Phase III Studies

Reversal Agents Against NOACs

Considerations for Using NOACs vs VKA

Unanswered Questions Remain Regarding the Use of NOACs

Phase 3 Data for NOACs in the Extended Treatment of VTE

Hokusai-VTE: Edoxaban vs Warfarin for the Treatment of Symptomatic VTE

Extending NOAC Treatment for the Prevention of VTE: Clinical Perspectives

Extending NOAC Treatment for the Prevention of VTE: Clinical Perspectives (cont)

Conclusions

Abbreviations

Abbreviations